Endocrine Today Current Issue
The following articles appeared in the print edition of Endocrine Today.
Table of Contents
- Childhood cancer survivors require lifelong vigilance for late endocrinopathies
-
- FDA approves nonadjunctive indication for Eversense CGM
- Treating hypertension reduces CV risks in diabetes care
- Replace diet discussions with focus on mindful eating Susan Weiner, MS, RDN, CDN, CDCES, FADCES
- Screen for fatty liver as a diabetes complication Jill Rollet
- FDA approves Victoza for children with type 2 diabetes
- New delivery options could make glucagon administration easier for people with diabetes, caregivers
- Adjunct therapies desired to reduce ‘constant daily burden’ of type 1 diabetes
- After 20-year increase, new diabetes cases decline 35%
-
- Fracture risk 73% higher after Roux-en-Y gastric bypass than adjustable gastric banding
- FRAX data suggest no increased fracture risk with aromatase inhibitor use
- High-activity radioiodine therapy acceptable for older adults with thyroid cancer
- ‘Substantial’ price increases continue for most popular brand-name drugs
- CREDENCE: Canagliflozin demonstrates CV, renal benefits in type 2 diabetes without CVD
- D2d: Vitamin D fails to prevent type 2 diabetes
- Diabetes coaching sparks HbA1c progress in pediatric type 1 diabetes
- ‘Medical bypass’ with triple gut-hormone infusion reduces glucose levels, body weight
-
- Personalized bionic pancreas increases time in range vs. usual care
- PIONEER: Oral semaglutide proves superior to empagliflozin, noninferior to liraglutide for lowering HbA1c
- PREVIEW: Intensive weight loss, behavior change prevents conversion to type 2 diabetes
- Teplizumab temporarily protects against type 1 diabetes in high-risk individuals
- Should pediatric cancer survivors previously exposed to neck irradiation undergo ultrasound screening for thyroid cancer?